DelveInsight's Cardiac Assist Devices Market Insights Report 2030 provides the current and forecast market analysis, individual leading companies market shares, challenges, Market Drivers, barriers, trends, and key market Cardiac Assist Devices Companies in the market. The Cardiac Assist Devices Market was valued at USD 2.89 billion in 2023, growing at a CAGR of 13.70% during the forecast period from 2024 to 2030, to reach USD 6.23 billion by 2030. North America is expected to hold the largest share of the Cardiac Assist Devices market in 2023, driven by several key factors. The leading Cardiac Assist Devices Companies such as Abbott Laboratories, Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc, CARMAT, CorWave SA, Medtronic PLC, Terumo Heart, Inc., NovaPump GmbH, Getinge AB, Balton Ltd., Meril Life Sciences Pvt. Ltd., Thoratec Corporation, CardiacAssist, Inc., Berlin Heart GmbH, BrioHealth Solutions, Inc., BiVACOR, Inc., Magenta Medical, Abiomed, SynCardia, and others. According to the British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, live with heart and circulatory diseases. Additionally, the prevalence of heart and circulatory diseases was 100 million in Europe and 340 million in Asia and Australia in 2021. Coronary (ischemic) heart disease, the most commonly diagnosed worldwide, affects an estimated 200 million people globally, with approximately 110 million men and 80 million women affected. Around 56 million women and 45 million men are stroke survivors. It is estimated that at least 13 million people worldwide live with congenital heart disease, with potentially millions more undiagnosed. The market is driven by the rise in prevalence of cardiovascular diseases such as heart failure and coronary artery disease, which has led to an increased need for cardiac assist devices. The scarcity of heart donors further intensifies this demand, as limited availability of donor organs leads to longer waiting times for transplantation, pushing patients and healthcare providers to seek alternative solutions such as cardiac assist devices. Increasing awareness and screening programs contribute to early detection and diagnosis of cardiovascular conditions, leading to higher patient referrals and a greater need for such assistive technologies. The market is also fueled by a surge in product launches and regulatory approvals from key market players, which introduces more advanced and effective cardiac assist devices, enhancing treatment options and competition among manufacturers, driving innovation and improvements in device technology during the forecast period from 2024 to 2030. The report covers the market by product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Artificial Heart, and Intra-Aortic Balloon Pump), type (Transcutaneous and Implantable), therapy (Bridge-To-Transplant (BTT) Therapy, Destination Therapy, and Bridge-To-Candidacy (BTC Therapy)), end-user (Hospitals, Cardiac Centers, and Ambulatory Surgical Centers), and geography (North America, Europe, Asia-Pacific, and Rest of the World).

Cardiac Assist Devices Market Size Report 2030 | DelveInsight

DelveInsight's 2030 market report on cardiac assist devices provides a comprehensive analysis of the global market, estimating its value at USD 2.89 billion in 2023, with a projected compound annual growth rate (CAGR) of 13.70% from 2024 to 2030, reaching USD 6.23 billion by 2030. North America is projected to hold the largest market share in 2023, driven by high prevalence of cardiovascular diseases, limited heart donor availability, and increasing demand for advanced cardiac assist technologies. The report highlights key market drivers including rising prevalence of heart failure and coronary artery disease, growing awareness and screening programs, and a surge in product launches and regulatory approvals. The market is segmented by product type, therapy, end-user, and geography. Globally, approximately 620 million people live with heart and circulatory diseases, with significant regional variations in prevalence, particularly in Europe and Asia and Australia. The report identifies leading companies such as Abbott Laboratories, Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc, CARMAT, CorWave SA, Medtronic PLC, Terumo Heart, Inc., NovaPump GmbH, Getinge AB, Balton Ltd., Meril Life Sciences Pvt. Ltd., Thoratec Corporation, CardiacAssist, Inc., Berlin Heart GmbH, BrioHealth Solutions, Inc., BiVACOR, Inc., Magenta Medical, Abiomed, and SynCardia as key players in the market.